Gene variants predict treatment success for alcoholism medication

January 19, 2011

The effectiveness of an experimental treatment for alcoholism depends on the genetic makeup of individuals who receive it, according to a new study supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health. A report of the findings appears online in the American Journal of Psychiatry.

"This study represents an important milestone in the search for personalized treatments for ," says NIAAA Acting Director Kenneth R. Warren, Ph.D.

Researchers led by Bankole Johnson, M.D., Ph.D., professor and chair of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, Charlottesville, conducted a controlled trial to determine if the medication ondansetron could reduce problem drinking, in alcohol-dependent individuals. Ondansetron is currently used to treat nausea and vomiting, often following chemotherapy. It works by blocking receptors for the brain chemical serotonin.

The current study extends the researchers’ previous work on the role the brain’s serotonin system plays in alcohol misuse. Serotonin mediates many processes in the brain, including the rewarding effects of alcohol. Dr. Johnson’s group has shown that variations in the gene that encodes the serotonin transporter, a protein that regulates the concentration of serotonin between nerve cells, can significantly influence drinking intensity. Specifically, serotonin transporter variants designated as LL and TT have been associated with more severe drinking problems. The researchers have also reported that ondansetron may be an effective therapy for some people with alcoholism.

In this study, Dr. Johnson and his colleagues performed genetic analyses to determine which gene variants were carried by each subject, then randomly assigned each subject to treatment regimens with ondansetron or placebo.

The researchers found that, for subjects with the LL genotype, those receiving ondansetron reduced their average number of daily drinks to less than five, while those receiving placebo continued to have five or more drinks per day. LL subjects who received ondansetron also had significantly more days of abstinence, relative to those who received placebo. Ondansetron’s effects were even more pronounced among individuals who possessed both the LL and TT gene variants, while subjects who lacked the LL variant showed no improvement with ondansetron.

"By being able to do genetic screening beforehand, clinicians can eliminate a great deal of the trial and error approach to prescribing medicine," says Dr. Johnson. "Personalized medicine allows them to better predict a successful treatment option."

Related Stories

Recommended for you

Suicidal thoughts rapidly reduced with ketamine, finds study

December 14, 2017
Ketamine was significantly more effective than a commonly used sedative in reducing suicidal thoughts in depressed patients, according to researchers at Columbia University Medical Center (CUMC). They also found that ketamine's ...

Do bullies have more sex?

December 14, 2017
Adolescents who are willing to exploit others for personal gain are more likely to bully and have sex than those who score higher on a measure of honesty and humility. This is according to a study in Springer's journal Evolutionary ...

Children's screen-time guidelines too restrictive, according to new research

December 14, 2017
Digital screen use is a staple of contemporary life for adults and children, whether they are browsing on laptops and smartphones, or watching TV. Paediatricians and scientists have long expressed concerns about the impact ...

Eating together as a family helps children feel better, physically and mentally

December 14, 2017
Children who routinely eat their meals together with their family are more likely to experience long-term physical and mental health benefits, a new Canadian study shows.

The iceberg model of self-harm

December 14, 2017
Researchers have created a model of self-harm that shows high levels of the problem in the community, especially in young girls, and the need for school-based prevention measures.

Anti-stress compound reduces obesity and diabetes

December 13, 2017
For the first time, scientists from the Max Planck Institute of Psychiatry in Munich could prove that a stress protein found in muscle has a diabetes promoting effect. This finding could pave the way to a completely new treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.